



# 3 Management Report



Quarter Ended September 30, 2025 This Management's Discussion and Analysis ("MD&A") of the financial condition and results of operations is intended to assist readers in understanding 5N Plus Inc. (the "Company" or "5N+"), its business environment, strategies, performance and risk factors. This MD&A should be read in conjunction with the unaudited condensed interim consolidated financial statements of Q3 2025 and the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2024, based on International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS Accounting Standards" or "IFRS"), unless otherwise stated. This MD&A has been prepared in accordance with the requirements of the Canadian Securities Administrators.

# All amounts in this MD&A are expressed in U.S. dollars, and all amounts in the tables are in thousands of U.S. dollars, unless otherwise indicated.

Information contained herein includes any significant developments until November 3, 2025, the date on which the MD&A was approved by the Company's Board of Directors. Unless otherwise indicated, the terms "we", "us", "our" and "the group" as used herein refer to the Company together with its subsidiaries. "Q3 2025" and "Q3 2024" refer to the three-month periods ended September 30, 2025, and September 30, 2024, respectively; "YTD 2025" and "YTD 2024" refer to the nine-month periods ended September 30, 2025, and September 30, 2024, respectively.

# **Non-IFRS Measures**

This MD&A contains certain non-IFRS financial measures, non-IFRS ratios, capital management measures and supplementary financial measures, which do not have a standard meaning under IFRS Accounting Standards and, therefore, may not be comparable to similar measures presented by other issuers. Such non-IFRS measures and ratios include Backlog, Bookings, EBITDA, EBITDA margin, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted operating expenses, Adjusted net earnings (loss), Basic adjusted earnings (loss) per share, Adjusted gross margin, Adjusted gross margin percentage, Total debt, Net debt, Net debt to EBITDA ratio, Working capital and Working capital ratio.

For definitions, further information and reconciliation of these measures to the most directly comparable measures under IFRS Accounting Standards, see the "Non-IFRS Measures" section.

# **Notice Regarding Forward-Looking Statements**

Certain statements in this MD&A may be forward-looking within the meaning of applicable securities laws. Such forwardlooking statements are based on a number of estimates and assumptions that the Company believes are reasonable when made, including that 5N+ will be able to retain and hire key personnel and maintain relationships with customers, suppliers and other business partners, that 5N+ will continue to operate its business in the normal course, that 5N+ will be able to implement its growth strategy, that 5N+ will be able to successfully and timely complete the realization of its backlog, that 5N+ will not suffer any supply chain challenges or any material disruption in the supply of raw materials on competitive terms, that 5N+ will be able to generate new sales, produce, deliver, and sell its expected product volumes at the expected prices and control its costs, as well as other factors believed to be appropriate and reasonable in the circumstances. However, there can be no assurance that such estimates and assumptions will prove to be correct. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict and may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A description of the risks affecting the Company's business and activities appears under the heading "Risk and Uncertainties" of 5N+'s 2024 MD&A dated February 25, 2025, and note 10 of the unaudited condensed interim consolidated financial statements for the three and nine-month periods ended September 30, 2025, and September 30, 2024, available on SEDAR+ at www.sedarplus.ca.

Forward-looking statements can generally be identified by the use of terms such as "may", "should", "would", "believe", "expect", the negative of these terms, variations of them or any similar terms. No assurance can be given that any events anticipated by the forward-looking statements in this MD&A will transpire or occur, or if any of them do so, what benefits that 5N+ will derive therefrom. In particular, no assurance can be given as to the future financial performance of 5N+.

The forward-looking statements contained in this MD&A is made as of the date hereof and the Company has no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. The reader is warned against placing undue reliance on these forward-looking statements. Forward-looking statements are presented in this MD&A for the purpose of assisting investors and others in understanding certain key elements of the Company's expected financial results, as well as the Company's

objectives, strategic priorities and outlook, and in obtaining a better understanding of the Company's anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

#### **Overview**

5N+ is a leading global producer of specialty semiconductors and performance materials. The Company's ultra-pure materials often form the core element of its customers' products. These customers rely on 5N+'s products to enable performance and sustainability in their own products. 5N+ deploys a range of proprietary and proven technologies to develop and manufacture its products. The Company's products enable various applications in several key industries, including renewable energy, security, space, pharmaceutical, medical imaging and industrial. Headquartered in Montreal, Québec, 5N+ operates R&D, manufacturing and commercial centers in strategically located facilities around the world including Europe, North America and Asia.

# Vision, Mission and Values

The Company's vision is to enable critical industries through essential products based on advanced material technology and 5N+'s aim is to propel the growth of these markets by developing and manufacturing advanced materials to enable product performance.

The Company's mission is to be critical to its customers, valued by its employees and trusted by its shareholders. The Company's core values are integrity, commitment and customer development, with an emphasis on sustainable development, continuous improvement, and health and safety.

#### **Reporting Segments**

The Company has the following two reportable segments: Specialty Semiconductors and Performance Materials. Corresponding operations and activities are managed accordingly by the Company's key decision makers. Segmented operating and financial information and labelled key performance indicators are available and used to manage these business segments, review performance and allocate resources. Financial performance of any given segment is evaluated primarily in terms of revenue and Adjusted EBITDA<sup>1</sup>, which are reconciled to consolidated numbers considering corporate income and expenses.

Operating in North America and Europe, the Specialty Semiconductors segment manufactures and sells products used in several applications, such as renewable energy, space satellites and imaging. Typical end markets include photovoltaics (terrestrial and space-related solar energy), medical imaging, infrared imaging, optoelectronics and advanced electronics. These products are sold either as semiconductor compounds, semiconductor wafers, ultra high purity metals, epitaxial semiconductor substrates, space solar cells and assemblies. Revenue and earnings associated with recycling services and activities provided to Specialty Semiconductors customers are captured in this segment.

The Performance Materials segment operates in North America, Europe and Asia and manufactures and sells products that are used in several applications in pharmaceutical and healthcare, and industrial. Main products are sold as active pharmaceutical ingredients, specialized chemicals, commercial grade metals, alloys and engineered powders. All commercial grade metal and engineered powder sales have been regrouped under Performance Materials. Revenue and earnings associated with recycling services and activities provided to Performance Materials customers are captured in this segment.

Corporate expenses associated with the head office and unallocated selling, general and administrative expenses (SG&A), together with financial expenses (income), are grouped under "Corporate".

5N--

<sup>&</sup>lt;sup>1</sup> These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

# Q3 2025 Highlights - Building on Strong Momentum and Rising Higher, Quarter after Quarter

5N+ has once again delivered an outstanding quarter, including record quarterly Adjusted EBITDA and its strongest quarterly revenue in a decade, further supported by record quarterly Adjusted gross margin¹ both in dollars and as a percentage of sales¹. In what continues to be a complex macro-environment, 5N+ is building on its strong momentum since the beginning of the year as the reliable partner of choice to customers across its strategic sectors.

The Company's ability to raise the bar quarter after quarter is possible thanks to its reliability, technical expertise and product quality, further reinforced by its diversified global sourcing and manufacturing capabilities. Our unique standing in the market, coupled with our competitive advantages and key differentiators, position 5N+ well through the remainder of the year.

#### All amounts are expressed in U.S. dollars.

In Q3 2025, the Company generated record quarterly revenue of \$104.9 million, representing 33% year-over-year growth. Factors contributing to this elevated performance include a 53% increase in revenue from the terrestrial renewable energy sector and a 41% increase in revenue from the space solar power sector.

5N+ also delivered a record quarterly Adjusted gross margin of 36.9% of sales, compared to 31.1% in Q3 2024, and Adjusted gross margin of \$38.7 million, representing a 58% increase over Q3 2024. Adjusted EBITDA reached a record \$29.1 million for Q3 2025, representing an increase of 86% compared to Q3 2024. These results reflect higher demand and volumes under Specialty Semiconductors and strong pricing for bismuth-based products despite lower volumes under Performance Materials, factors consistent with the previous quarter.

Specialty Semiconductors revenue in Q3 2025 was \$75.2 million, compared to \$53.0 million in Q3 2024, supported by higher demand from the terrestrial renewable energy and space solar power sectors. Adjusted gross margin as a percentage of sales was 30.8% in Q3 2025, compared to 24.8% in Q3 2024, favourably impacted by economies of scale from higher production and higher prices net of inflation. Adjusted EBITDA in Q3 2025 increased by \$10.4 million, or 120%, to reach \$19.2 million, driven by the same factors. Segment backlog¹ represented 365 days of annualized revenue, while the effective backlog for the renewable energy and space solar power sectors specifically continued to surpass 365 days at period end.

Performance Materials revenue in Q3 2025 reached \$29.7 million, compared to \$25.9 million in Q3 2024 and Adjusted gross margin as a percentage of sales was 53.1% in Q3 2025, compared to 44.4% in Q3 2024, impacted by a favourable inventory position, product mix, higher prices net of inflation and higher metal input costs. Adjusted EBITDA in Q3 2025 increased by \$3.7 million, or 39%, to reach \$13.3 million, driven by the same factors. Backlog for Performance Materials represented 104 days of annualized revenue at period end, reflecting the timing of contract signing and/or renewals, net of the quarterly realization of long-term contracts.

The Company maintained its strong financial position during the quarter with Net debt<sup>1</sup> at the low level of \$63.3 million as at September 30, 2025, compared to \$100.1 million as at December 31, 2024, bringing its net-debt-to-EBITDA ratio<sup>1</sup> to 0.74x at quarter end.

# **Financial Highlights**

- Revenue in Q3 2025 increased by 33% to \$104.9 million, compared to \$78.8 million in Q3 2024. The increase is
  primarily attributable to higher sales in the terrestrial renewable energy and space solar power sectors under
  Specialty Semiconductors, and higher bismuth-based product pricing under Performance Materials.
- Adjusted EBITDA in Q3 2025 increased by 86% to \$29.1 million, compared to \$15.6 million in Q3 2024, driven by higher volumes in the terrestrial renewable energy and space solar power sectors, and better prices over inflation for both space solar power and bismuth-based products.

<sup>&</sup>lt;sup>1</sup> These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

- Adjusted gross margin increased by 58% to \$38.7 million in Q3 2025, favourably impacted by the same factors as above. Adjusted gross margin as a percentage of sales was 36.9% in Q3 2025, compared to 31.1% in Q3 2024.
- Net earnings in Q3 2025 were \$18.2 million, compared to \$6.4 million in Q3 2024.
- Backlog stood at \$357.5 million, representing 311 days of annualized revenue as at September 30, 2025, 14 days higher than in the previous quarter.
- Net debt was \$63.3 million as at September 30, 2025, compared to \$100.1 million as at December 31, 2024, reflecting an increase in operating cashflows. The Company's net-debt-to-EBITDA ratio stood at 0.74x as at September 30, 2025.

# **CEO Succession Plan**

On October 29, 2025, the Company announced its CEO succession plan, with the appointment of Richard Perron as President, effective November 1, 2025, in addition to his role of CFO. Gervais Jacques will remain CEO until Mr. Perron assumes the role of President and CEO, effective May 31, 2026, at which time Mr. Jacques will become Executive Chairman of the Board.

#### **Outlook**

For the remainder of 2025, 5N+ anticipates demand under Specialty Semiconductors from the terrestrial renewable energy and space solar power markets to remain strong, as customers continue to secure advanced materials from trusted and reliable partners. Under Performance Materials, consistent with historical trends, volumes through the end of 2025 are expected to be slightly lower than compared to the first half of 2025, with margins continuing to benefit from the Company's strategic global footprint and sourcing capabilities in the current volatile business environment.

Based on its financial performance in the first three quarters of the year, coupled with anticipated seasonality impact and other operational factors, Adjusted EBITDA guidance for 2025 has been revised upwards from a range of \$65 to \$70 million, last updated on August 4, 2025, to a range of \$85 to \$90 million.

Looking ahead, the Company will continue to remain prudent in an evolving geopolitical environment, including with regards to its impact on operating costs. As a preferred supplier of ultra-high-purity, high-quality products with a strong supply chain providing customers with a key strategic advantage, 5N+ is well-positioned to continue solidifying its leadership in key end markets through the end of 2025 and going into 2026.

# **Summary of Results**

(in thousands of U.S. dollars, except per share amounts)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Revenue	104,895	78,828	289,094	218,427
Adjusted operating expenses <sup>1</sup>	(75,840)	(63,207)	(215,101)	(177,579)
Adjusted EBITDA	29,055	15,621	73,993	40,848
Share-based compensation recovery (expense)	2,512	(252)	1,926	(597)
Gain on disposal of property, plant and equipment	-	2,089	-	2,089
Impairment of non-current assets	-	(2,519)	-	(2,826)
ERP implementation costs	(343)	-	(659)	-
Loss on remeasurement of financial instrument	-	-	(1,000)	-
Litigation and restructuring costs	-	(1,021)	-	(1,021)
Foreign exchange gain	522	450	1,333	835
EBITDA <sup>1</sup>	31,746	14,368	75,593	39,328
Interest on long-term debt, imputed interest and other interest expense	2,293	2,643	7,363	6,723
Depreciation and amortization	4,495	4,424	12,947	12,418
Earnings before income taxes	24,958	7,301	55,283	20,187
Income tax expense (recovery)				
Current	5,526	1,347	13,603	6,038
Deferred	1,256	(416)	(1,296)	483
	6,782	931	12,307	6,521
Net earnings	18,176	6,370	42,976	13,666
Basic earnings per share	\$0.20	\$0.07	\$0.48	\$0.15
Diluted earnings per share	\$0.20	\$0.07	\$0.48	\$0.15

# **Revenue by Segment and Adjusted Gross Margin**

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	Change	YTD 2025	YTD 2024	Change
	\$	\$		\$	\$	
Specialty Semiconductors	75,208	52,973	42%	209,225	150,463	39%
Performance Materials	29,687	25,855	15%	79,869	67,964	18%
Total revenue	104,895	78,828	33%	289,094	218,427	32%
Cost of sales	(69,857)	(57,904)	21%	(197,637)	(160,309)	23%
Depreciation included in cost of sales	3,703	3,553	4%	10,657	9,802	9%
Adjusted gross margin	38,741	24,477	58%	102,114	67,920	50%
Adjusted gross margin percentage	36.9%	31.1%		35.3%	31.1%	

Revenue in Q3 2025 increased by 33%, reaching \$104.9 million, compared to \$78.8 million for the same period last year. Revenue in YTD 2025 reached \$289.1 million, compared to \$218.4 million in YTD 2024. The increases are primarily attributable to strong growth from the terrestrial renewable energy and space solar power sectors under Specialty Semiconductors and continued favourable pricing from bismuth-based products under Performance Materials.

Adjusted gross margin increased by 58% to reach \$38.7 million in Q3 2025, compared to \$24.5 million in Q3 2024, and \$102.1 million in YTD 2025, compared to \$67.9 million in the same period last year, favourably impacted by higher volumes in strategic sectors under Specialty Semiconductors and better prices over inflation so far this year. Adjusted gross margin as a percentage of sales was 36.9% in Q3 2025, compared to 31.1% in Q3 2024, with a favourable year-over-year product mix and pricing over metal input costs under Performance Materials. Adjusted gross margin as a percentage of sales was 35.3% in YTD 2025, compared to 31.1% in YTD 2024.

<sup>&</sup>lt;sup>1</sup> These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

# **Specialty Semiconductors**

Revenue in Q3 2025 was \$75.2 million, compared to \$53.0 million in Q3 2024. In YTD 2025, revenue was \$209.2 million, compared to \$150.5 million in YTD 2024, supported by higher demand from the terrestrial renewable energy and space solar power sectors. Adjusted gross margin as a percentage of sales was 30.8% in Q3 2025, compared to 24.8% in Q3 2024. Adjusted gross margin as a percentage of sales was 32.7% in YTD 2025, compared to 29.0% in YTD 2024, favourably impacted by economies of scale from higher production and higher prices net of inflation.

#### **Performance Materials**

Revenue in Q3 2025 reached \$29.7 million, compared to \$25.9 million in Q3 2024. In YTD 2025, revenue was \$79.9 million, compared to \$68.0 million in YTD 2024. Adjusted gross margin as a percentage of sales was 53.1% in Q3 2025, compared to 44.4% in Q3 2024. Adjusted gross margin as a percentage of sales was 42.9% in YTD 2025, compared to 36.5% in YTD 2024, impacted by a favourable inventory position at the beginning of the period, product mix, higher prices net of inflation and higher metal input costs.

# **Operating Earnings, EBITDA and Adjusted EBITDA**

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	Change	YTD 2025	YTD 2024	Change
	\$	\$		\$	\$	
Specialty Semiconductors	19,169	8,732	120%	55,844	31,361	78%
Performance Materials	13,267	9,573	39%	27,372	18,344	49%
Corporate	(3,381)	(2,684)	26%	(9,223)	(8,857)	4%
Adjusted EBITDA	29,055	15,621	86%	73,993	40,848	81%
EBITDA	31,746	14,368	121%	75,593	39,328	92%
Operating earnings	26,729	9,494	182%	61,313	26,075	135%

Adjusted EBITDA in Q3 2025 increased by 86% to \$29.1 million, representing an Adjusted EBITDA margin<sup>1</sup> of 27.7%, compared to \$15.6 million, or an Adjusted EBITDA margin of 19.8%, in Q3 2024. Adjusted EBITDA was \$74.0 million in YTD 2025, an 81% increase compared to \$40.8 million in YTD 2024.

In Q3 2025, EBITDA reached \$31.7 million, compared to \$14.4 million in Q3 2024. The increase of \$17.4 million is mainly explained by an increase in Adjusted EBITDA. The items reconciling Adjusted EBITDA to EBITDA are share-based compensation recovery, ERP implementation costs, and a foreign exchange gain. For more information, see the "Expenses" section.

In Q3 2025, operating earnings amounted to \$26.7 million, compared to operating earnings of \$9.5 million in Q3 2024, impacted by the same factors as mentioned above. In YTD 2025, operating earnings amounted to \$61.3 million, compared to \$26.1 million in YTD 2024.

# **Specialty Semiconductors**

Adjusted EBITDA in Q3 2025 increased by \$10.4 million, or 120%, to reach \$19.2 million, representing an Adjusted EBITDA margin of 25.5%, compared to 16.5% in Q3 2024. Adjusted EBITDA in YTD 2025 increased by \$24.5 million to \$55.8 million, representing an Adjusted EBITDA margin of 26.7%, compared to 20.8% for the same period in 2024. The increase is primarily attributable to higher demand in the terrestrial renewable energy and space solar power sectors, higher prices net of inflation and favourable unit costs from economies of scale.

#### **Performance Materials**

Adjusted EBITDA in Q3 2025 increased by \$3.7 million, or 39%, and reached \$13.3 million, representing an Adjusted EBITDA margin of 44.7%, compared to 37.0% in Q3 2024. Adjusted EBITDA in YTD 2025 increased by \$9.0 million to \$27.4 million, representing an Adjusted EBITDA margin of 34.3%, compared to 27.0% in the same period in 2024. The increase is primarily attributable to a favourable inventory position at the beginning of the period, product mix, higher prices net of inflation and higher metal input costs.

<sup>&</sup>lt;sup>1</sup> These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

# **Net Earnings and Adjusted Net Earnings**

Q3 2025	Q3 2024	YTD 2025	YTD 2024
\$	\$	\$	\$
18,176	6,370	42,976	13,666
\$0.20	\$0.07	\$0.48	\$0.15
(2,512)	252	(1,926)	597
-	(2,089)	-	(2,089)
-	2,519	-	2,826
343	-	659	-
-	-	1,000	-
-	1,021	-	1,021
575	(232)	337	(417)
16,582	7,841	43,046	15,604
\$0.19	\$0.09	\$0.48	\$0.18
	\$ 18,176 \$0.20  (2,512) 343 - 575	\$ \$ \$ \$ 18,176 6,370 \$0.20 \$0.07  (2,512) 252 - (2,089) - 2,519 343 1,021 575 (232) 16,582 7,841	\$ \$ \$ \$ \$ \$ \$ \$ 18,176 6,370 42,976 \$0.20 \$0.07 \$0.48  (2,512) 252 (1,926) - (2,089) - 2,519 - 343 - 659 - 1,000 - 1,021 - 1,000 575 (232) 337 16,582 7,841 43,046

In Q3 2025, net earnings were \$18.2 million, or \$0.20 per share, compared to net earnings of \$6.4 million, or \$0.07 per share, in Q3 2024, positively impacted by higher year-over-year Adjusted EBITDA when compared to Q3 2024. Adjusted net earnings were \$16.6 million, or \$0.19 per share, in Q3 2025, compared to \$7.8 million, or \$0.09 per share, in Q3 2024.

In YTD 2025, net earnings were \$43.0 million, or \$0.48 per share, compared to \$13.7 million, or \$0.15 per share, in YTD 2024. Adjusted net earnings were \$43.0 million, or \$0.48 per share, in YTD 2025, compared to \$15.6 million or \$0.18 per share in YTD 2024.

Excluding income tax expense, the items reconciling Adjusted net earnings in Q3 2025 and YTD 2025 are a share-based compensation recovery, ERP implementation costs and loss on remeasurement of financial instrument. For more information, see the "Expenses" section.

# **Backlog and Bookings**

	BACKLOG			BOOKINGS <sup>1</sup>		
(in thousands of U.S. dollars)	Q3 2025	Q2 2025	Q3 2024	Q3 2025	Q2 2025	Q3 2024
	\$	\$	\$	\$	\$	\$
Specialty Semiconductors	323,860	276,400	218,200	122,668	115,981	55,748
Performance Materials	33,678	33,629	31,493	29,736	28,428	27,726
Total	357,538	310,029	249,693	152,404	144,409	83,474

	BACKLOG			BACKLOG BOOKINGS			
(number of days based on annualized revenue)*	Q3 2025	Q2 2025	Q3 2024	Q3 2025	Q2 2025	Q3 2024	
Specialty Semiconductors	365	354	365	149	149	96	
Performance Materials	104	127	111	91	108	98	
Weighted average	311	297	289	133	138	97	

<sup>\*</sup> Backlog and bookings are also presented in number of days to normalize the impact of commodity prices.

# Q3 2025 vs. Q2 2025

Backlog on September 30, 2025, represented 311 days of annualized revenue, 14 days higher than the backlog on June 30, 2025.

The backlog for Specialty Semiconductors represented 365 days of annualized revenue, 11 days higher than the backlog on June 30, 2025. While the estimated number of days based on annualized revenue cannot exceed 365 days per the Company's definition of backlog, the effective backlog under Specialty Semiconductors for the terrestrial renewable energy and space solar power sectors specifically surpassed the next twelve months on September 30, 2025.

<sup>&</sup>lt;sup>1</sup> These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

The backlog for Performance Materials represented 104 days of annualized revenue, 23 days lower than the backlog on June 30, 2025, mainly due to the timing of contract signing and/or renewals, net of the quarterly realization of long-term contracts.

Bookings for Specialty Semiconductors were at the same level as in Q2 2025 at 149 days. Bookings for Performance Materials in Q3 2025 decreased by 17 days, from 108 days in Q2 2025 to 91 days in Q3 2025. Bookings are calculated by adding revenue to the increase or decrease in backlog for the period divided by annualized revenue. As such, the increase or decrease in bookings is attributable to the same factors as the increase or decrease in backlog.

# Q3 2025 vs. Q3 2024

Backlog for Specialty Semiconductors on September 30, 2025, was at the same level as on September 30, 2024, at 365 days. Backlog for Performance Materials on September 30, 2025, represented 104 days, a decrease of 7 days when compared to 111 days on September 30, 2024.

Bookings increased by 53 days for Specialty Semiconductors and decreased by 7 days for Performance Materials when compared to Q3 2024.

# **Expenses**

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Depreciation and amortization	4,495	4,424	12,947	12,418
SG&A	8,944	8,135	25,203	24,169
Share-based compensation (recovery) expense	(2,512)	252	(1,926)	597
Gain on disposal of property, plant and equipment	-	(2,089)	-	(2,089)
Impairment of non-current assets	-	2,519	-	2,826
ERP implementation costs	343	-	659	-
Loss on remeasurement of financial instrument	-	-	1,000	-
Litigation and restructuring costs	-	1,021	-	1,021
Financial expense	1,771	2,193	6,030	5,888
Income tax expense	6,782	931	12,307	6,521
Total expenses	19,823	17,386	56,220	51,351

# **Depreciation and Amortization**

Depreciation and amortization expenses in Q3 2025 and YTD 2025 amounted to \$4.5 million and \$12.9 million, respectively, compared to \$4.4 million and \$12.4 million, respectively, for the same periods in 2024.

# SG&A

Sales, General & Administrative ("SG&A") expenses in Q3 2025 and YTD 2025 were \$8.9 million and \$25.2 million, respectively, compared to \$8.1 million and \$24.2 million, respectively, for the same periods in 2024.

#### Share-based Compensation (Recovery) Expense

Share-based compensation recovery in Q3 2025 amounted to \$2.5 million, compared to a share-based compensation expense of \$0.3 million Q3 2024. In YTD 2025, share-based compensation recovery amounted to \$1.9 million, compared to a share-based compensation expense of \$0.6 million in YTD 2024. The Company holds a total return swap to reduce its exposure to its share price fluctuations relating to DSU, PSU, RSU and SAR for a volume slightly above the current outstanding granted volume.

# Gain on Disposal of Property, Plant and Equipment

During Q3 2024, the Company recognized a gain of \$2.1 million in relation to the sale of unused production equipment under Performance Materials following the Company's decision to switch to higher capacity equipment.

# **Impairment of Non-Current Assets**

During Q3 2024, the Company recorded an impairment of non-current assets of \$1.7 million in relation to intangible assets under Performance Materials, to reflect the assessment of the carrying value of technology and development costs following the Company's sale of unused production equipment.

During Q3 2024, the Company recorded an impairment of non-current assets of \$0.6 million in relation to property, plant and equipment under Performance Materials, to reflect the assessment of the carrying value of production equipment following the Company's decision to prioritize specific production operations to support the Company's core business.

During Q2 and Q3 2024, the Company recorded an impairment of non-current assets of \$0.3 million and \$0.3 million, respectively, in relation to property, plant and equipment under Specialty Semiconductors, to reflect the assessment of the carrying value of production equipment following the Company's decision to discontinue construction of the asset.

#### **ERP Implementation Costs**

Enterprise Resource Planning ("ERP") implementation costs of \$0.3 million and \$0.7 million were incurred in Q3 2025 and YTD 2025, respectively, in relation to project implementation at the Company's Montréal, Quebec site. The project, originally anticipated to be completed by the end of 2025, is now expected to extend into Q1 2026.

# **Loss on Remeasurement of Financial Instrument**

In June 2025, a remeasurement loss on financial assets was recorded for \$1.0 million based on the revised estimates of the fair value of the Company's equity instrument in Microbion Corporation (Microbion) to reflect the increased difficulties for pharmaceutical research companies to raise capital.

# **Litigation and Restructuring Costs**

In Q3 2024, the Company recorded litigation and restructuring costs comprised of a provision of \$0.4 million related to a deposit for which it is probable that it is refundable to a client, \$0.4 million related to site closures in Asia and \$0.2 million related to changes in management.

# **Financial Expense**

Financial expense amounted to \$1.8 million in Q3 2025, compared to \$2.2 million in Q3 2024. In YTD 2025, financial expense amounted to \$6.0 million, compared to \$5.9 million in YTD 2024.

# **Income Taxes**

The Company reported earnings before income taxes of \$25.0 million in Q3 2025 and of \$55.3 million in YTD 2025. Income tax expense in Q3 2025 and YTD 2025 was \$6.8 million and \$12.3 million, respectively, compared to \$0.9 million and \$6.5 million, respectively, in the same periods in 2024. Both years were impacted by deferred tax assets applicable only in certain jurisdictions.

# **Liquidity and Capital Resources**

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Cash from operations before the following:	21,848	11,875	56,492	28,522
Net changes in non-cash working capital items	(4,109)	(13,090)	(10,099)	(32,355)
Cash from (used in) operating activities	17,739	(1,215)	46,393	(3,833)
Cash used in investing activities	(5,559)	(1,045)	(7,103)	(15,521)
Cash (used in) from financing activities	(8,295)	(551)	(9,665)	9,155
Effect of foreign exchange rate changes on cash	(317)	231	425	58
Net increase (decrease) in cash	3,568	(2,580)	30,050	(10,141)

In Q3 2025, cash from operating activities amounted to \$17.7 million, compared to cash used in operating activities of \$1.2 million for the same period in 2024. In YTD 2025, cash from operating activities amounted to \$46.4 million, compared to cash used in operating activities of \$3.8 million in YTD 2024. The positive variance of \$50.2 million is due to a higher contribution in cash from operations of \$28.0 million from higher EBITDA and a favourable variance in working capital requirements of \$22.3 million.

In Q3 2025, cash used in investing activities amounted to \$5.6 million, compared to \$1.0 million in Q3 2024. In YTD 2025, cash used in investing activities amounted to \$7.1 million, compared to \$15.5 million in YTD 2024. The positive variance of \$8.4 million is mainly explained by the proceeds on settlement of the Company's total return swap renewed in

Q1 2025, resulting in a receipt of cash of \$6.9 million and decreased additions to property, plant and equipment of \$4.3 million compared to YTD 2024, partially offset by a decrease in proceeds of disposition on property, plant and equipment of \$3.7 million.

In Q3 2025, cash used in financing activities amounted to \$8.3 million, compared to \$0.6 million in Q3 2024. In YTD 2025, cash used in financing activities amounted to \$9.7 million, compared to cash generated in financing activities of \$9.2 million in YTD 2024, creating a negative variance of \$18.8 million. In YTD 2024, the Company needed to drawdown funds from its credit facility to repay a portion of its subordinated loan as well as for investment purposes. While in YTD 2025, the Company had the capacity to reimburse a portion of its credit facility following its strong operating cashflows. In addition, the Company received from interest-free term loans a total amount of \$2.9 million in YTD 2024 compared to \$0.9 million in YTD 2025.

# **Working Capital**

(in thousands of U.S. dollars)	As at September 30, 2025	As at December 31, 2024
	\$	\$
Inventories	153,792	137,823
Other current assets	135,759	79,572
Current liabilities	(97,406)	(60,481)
Working capital <sup>1</sup>	192,145	156,914
Working capital ratio <sup>1</sup>	2.97	3.59

Working capital increased by \$35.2 million as at September 30, 2025, to \$192. 1 million, compared to \$156.9 million as at December 31, 2024, due to an increase in other current assets of \$56.2 million from higher revenue and an increase in inventory of \$16.0 million to support demand, partially offset by higher current liabilities of \$36.9 million.

# **Net Debt**

(in thousands of U.S. dollars)	As at September 30, 2025	As at December 31, 2024
	\$	\$
Bank indebtedness	-	-
Long-term debt including current portion	115,471	122,203
Total debt <sup>1</sup>	115,471	122,203
Cash	(52,192)	(22,142)
Net debt	63,279	100,061

Total debt stood at \$115.5 million as at September 30, 2025, compared to \$122.2 million as at December 31, 2024.

Net debt, after considering cash, decreased by \$36.8 million, to \$63.3 million as at September 30, 2025, from \$100.1 million as at December 31, 2024.

In March 2025, the Company signed a senior secured multi-currency revolving credit facility of \$154.0 million maturing in March 2029 to replace its \$124.0 million senior secured revolving facility maturing in April 2026. At any time, the Company has the option to request that the credit facility be expanded through the exercise of an additional \$50.0 million accordion feature, subject to review and approval by the lenders. This revolving credit facility can be drawn in U.S. dollars, Canadian dollars or Hong Kong dollars (up to \$4.0 million). Drawings bear interest at either the Canadian prime rate, U.S. base rate, Hong Kong base rate, SOFR or CORRA, plus a margin based on the Company's senior net-debt-to-consolidated-EBITDA ratio. Under the terms of its credit facility, the Company is required to satisfy certain restrictive covenants as to financial ratios. As at September 30, 2025, and December 31, 2024, the Company had met all covenants.

In addition, in March 2025, the Company received CA\$1.3 million from Canada Economic Development for Quebec Regions with respect to an interest-free term loan with a maximum drawdown of CA\$3.0 million dependent upon eligible

<sup>&</sup>lt;sup>1</sup> These measures are not recognized measures under IFRS and do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. See Non-IFRS Measures for more information.

capital expenditures, bringing the Company's total drawdown to CA\$2.5 million. Upon completion of the capital project but no later than December 31, 2025, the Company will benefit from a two-year repayment moratorium period on the interest-free loan. Subsequently, the loan is reimbursable in monthly instalments over a period of five years.

#### **Share Information**

	As at November 3, 2025	As at September 30, 2025
Issued and outstanding shares	89,074,051	89,074,051
Stock options potentially issuable	1,203,674	1,203,674

# **Off-balance Sheet Arrangements**

The Company is exposed to currency risk on sales in euros and other currencies, as well as interest rate fluctuations on its credit facility, and, therefore, may periodically enter foreign currency forward contracts and interest rate or foreign currency swap contracts to protect itself against interest rate and currency fluctuations. The reader will find more details related to these contracts in Notes 18 and 26 of the audited consolidated financial statements for the year ended December 31, 2024.

#### Commitments

In the normal course of business, the Company contracted letters of credit for an amount of \$0.3 million as at September 30, 2025, and of \$0.2 million as at December 31, 2024.

# **Contingencies**

In the normal course of operations, the Company is exposed to events that could give rise to contingent liabilities or assets. As at the date of issue of the consolidated financial statements, the Company was not aware of any significant events that would have a material effect on its consolidated financial statements.

#### Governance

As required by Multilateral Instrument 52-109 of the Canadian Securities Administrators ("MI 52-109"), 5N+ has filed certificates signed by the Chief Executive Officer ("CEO") and the Chief Financial Officer ("CFO") that, among other things, attest to the design of the disclosure controls and procedures and the design and effectiveness of internal controls over financial reporting.

# **Disclosure Controls and Procedures**

The CEO and the CFO have designed disclosure controls and procedures ("DC&P"), or have caused them to be designed under their supervision, to provide reasonable assurance that:

- Material information relating to the Company has been made known to them; and
- Information required to be disclosed in the Company's filings is recorded, processed, summarized and reported within the time periods specified in securities legislation.

An evaluation of the effectiveness of the Company's disclosure controls and procedures was carried out under the supervision of the CEO and CFO. Based on this evaluation, the CEO and the CFO concluded that the disclosure controls and procedures are effective.

# **Internal Control over Financial Reporting**

The CEO and the CFO have also designed internal controls over financial reporting (ICFR) or have caused them to be designed under their supervision, using the Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO Framework), to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS Accounting Standards.

Due to their intrinsic limitations, DC&P and ICFR only provide reasonable assurance and may not prevent or detect all misstatement or errors.

# **Changes in Internal Control over Financial Reporting**

No changes were made to the ICFR during the nine-month period ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, the ICFR.

# **Financial Instruments and Risk Management**

#### **Fair Value of Financial Instruments**

A detailed description of the methods and assumptions used to measure the fair value of the Company's financial instruments and their fair value is discussed in Note 18 – Fair Value of Financial Instruments of the audited consolidated financial statements for the year ended December 31, 2024.

# **Financial Risk Management**

For a detailed description of the nature and extent of risks arising from financial instruments, and their related risk management, refer to Note 26 of the audited consolidated financial statements for the year ended December 31, 2024.

#### **Risk and Uncertainties**

For a detailed description of risk factors associated with 5N+ and its business, refer to "Risk and Uncertainties" of 5N+' 2024 MD&A dated February 25, 2025. Factors of uncertainty and risk that might result in such differences include the risks associated with interest rate, foreign currency, credit, liquidity, global economic conditions, international operations including China and trade protectionist measures and any retaliatory action from affected countries, environmental regulations, crisis and climate change management, environmental social and governance (ESG) considerations, safety and hazards, prolonged armed conflict in Ukraine, disease outbreaks, availability and retention of qualified professional employees, collective agreements, litigation, our growth strategy, competition, commodity price, sources of supply, protection of intellectual property, inventory price, business interruptions, loss of an important customer, changes to backlog, acquisitions, systems, network infrastructure and data failure, interruption and breach, privacy, market price of the common shares, as well as grants and other incentive programs.

# **Non-IFRS Measures**

In this MD&A, certain non-IFRS measures are used. The Company's management believes that these non-IFRS measures provide useful information to investors regarding the Company's financial condition and results of operations as they provide additional key metrics of its performance. These non-IFRS measures are not recognized under IFRS Accounting Standards, do not have any standardized meaning prescribed under IFRS Accounting Standards and may differ from similarly named measures as reported by other issuers, and accordingly may not be comparable. These measures should not be viewed as a substitute for the related financial information prepared in accordance with IFRS Accounting Standards.

Backlog represents the expected orders the Company has received, but has not yet executed, and that are expected to translate into sales within the next twelve months, expressed in dollars and estimated in number of days not to exceed 365 days. Bookings represent orders received during the period considered, expressed in number of days, and calculated by adding revenue to the increase or decrease in backlog for the period considered, divided by annualized year revenue. 5N+ uses backlog to provide an indication of expected future revenue in days, and bookings to determine its ability to sustain and increase its revenue.

EBITDA means net earnings (loss) before interest expenses, income tax expense (recovery), depreciation and amortization. 5N+ uses EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business, without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

EBITDA is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Net earnings	18,176	6,370	42,976	13,666
Interest on long-term debt, imputed interest and other interest expense	2,293	2,643	7,363	6,723
Income tax expense	6,782	931	12,307	6,521
Depreciation and amortization	4,495	4,424	12,947	12,418
EBITDA	31,746	14,368	75,593	39,328

EBITDA margin is defined as EBITDA divided by revenue.

Adjusted EBITDA means operating earnings (loss) as defined before the effect of impairment of inventories, share-based compensation expense (recovery), ERP implementation costs, loss (gain) on disposal of property, plant and equipment, loss (gain) on remeasurement of financial instrument, impairment (reversal of impairment) of non-current assets, litigation and restructuring costs (income), and depreciation and amortization. 5N+ uses Adjusted EBITDA because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of certain expenses. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

Adjusted EBITDA margin is defined as Adjusted EBITDA divided by revenue.

Adjusted EBITDA and Adjusted EBITDA margin are reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Revenue	104,895	78,828	289,094	218,427
Operating expenses	(78,166)	(69,334)	(227,781)	(192,352)
Operating earnings	26,729	9,494	61,313	26,075
Share-based compensation (recovery) expense	(2,512)	252	(1,926)	597
Gain on disposal of property, plant and equipment	-	(2,089)	-	(2,089)
Impairment of non-current assets	-	2,519	-	2,826
ERP implementation costs	343	-	659	-
Loss on remeasurement of financial instrument	-	-	1,000	-
Litigation and restructuring costs	-	1,021	-	1,021
Depreciation and amortization	4,495	4,424	12,947	12,418
Adjusted EBITDA	29,055	15,621	73,993	40,848
Adjusted EBITDA margin	27.7%	19.8%	25.6%	18.7%

Adjusted operating expenses means operating expenses before impairment of inventories, share-based compensation expense (recovery), ERP implementation costs, loss (gain) on disposal of property, plant and equipment, loss (gain) on remeasurement of financial instrument, impairment (reversal of impairment) of non-current assets, litigation and restructuring costs (income), and depreciation and amortization. 5N+ uses Adjusted operating expenses to calculate Adjusted EBITDA. 5N+ believes it is a meaningful measure of the operating performance of its ongoing business. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

Adjusted operating expenses are reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Operating expenses	78,166	69,334	227,781	192,352
Share-based compensation recovery (expense)	2,512	(252)	1,926	(597)
Gain on disposal of property, plant and equipment	-	2,089	-	2,089
Impairment of non-current assets	-	(2,519)	-	(2,826)
ERP implementation costs	(343)	-	(659)	-
Loss on remeasurement of financial instrument	-	-	(1,000)	-
Litigation and restructuring costs	-	(1,021)	-	(1,021)
Depreciation and amortization	(4,495)	(4,424)	(12,947)	(12,418)
Adjusted operating expenses	75,840	63,207	215,101	177,579

Adjusted net earnings (loss) means the net earnings (loss) before the effect of impairment of inventory, share-based compensation expense (recovery), ERP implementation costs, loss (gain) on disposal of property, plant and equipment, loss (gain) on remeasurement of financial instrument, impairment (reversal of impairment) of non-current assets and litigation and restructuring costs (income), net of the related income tax expense (recovery). 5N+ uses adjusted net earnings (loss) because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of unusual expenses or income. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

Basic adjusted earnings (loss) per share means adjusted net earnings (loss) divided by the basic weighted average number of outstanding shares. 5N+ uses basic adjusted earnings (loss) per share because it believes it is a meaningful measure of the operating performance of its ongoing business without the effects of unusual expenses or income. The definition of this non-IFRS measure used by the Company may differ from that used by other companies.

Adjusted net earnings (loss) and Basic adjusted earnings (loss) per share are reconciled to the most comparable IFRS measures:

(in thousands of U.S. dollars, except per share amounts and number of shares)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Net earnings	18,176	6,370	42,976	13,666
Basic earnings per share	\$0.20	\$0.07	\$0.48	\$0.15
Reconciling items:				
Share-based compensation (recovery) expense	(2,512)	252	(1,926)	597
Gain on disposal of property, plant and equipment	-	(2,089)	-	(2,089)
Impairment of non-current assets	-	2,519	-	2,826
ERP implementation costs	343	-	659	-
Loss on remeasurement of financial instrument	-	-	1,000	-
Litigation and restructuring costs	-	1,021	-	1,021
Income tax expense (recovery) on taxable items above	575	(232)	337	(417)
Adjusted net earnings	16,582	7,841	43,046	15,604
Basic weighted average number of shares	89,073,847	88,947,692	89,057,751	88,833,561
Basic adjusted earnings per share	\$0.19	\$0.09	\$0.48	\$0.18

Adjusted gross margin is a measure used to monitor the sales contribution after paying cost of sales, excluding depreciation and inventory impairment charges. 5N+ also expressed this measure in percentage of revenue by dividing the adjusted gross margin value by the total revenue.

Adjusted gross margin is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)	Q3 2025	Q3 2024	YTD 2025	YTD 2024
	\$	\$	\$	\$
Total revenue	104,895	78,828	289,094	218,427
Cost of sales	(69,857)	(57,904)	(197,637)	(160,309)
Gross margin	35,038	20,924	91,457	58,118
Depreciation included in cost of sales	3,703	3,553	10,657	9,802
Adjusted gross margin	38,741	24,477	102,114	67,920
Adjusted gross margin percentage	36.9%	31.1%	35.3%	31.1%

Net debt is calculated as total debt less cash. Any introduced IFRS 16 reporting measures in reference to lease liabilities are excluded from the calculation. 5N+ uses this measure as an indicator of its overall financial position.

The net debt to EBITDA ratio is defined as net debt divided by the trailing 12 months EBITDA.

Total debt and Net debt are reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)	As at September 30, 2025	As at December 31, 2024
	\$	\$
Bank indebtedness	-	-
Long-term debt including current portion	115,471	122,203
Lease liabilities including current portion	30,364	29,402
Subtotal Debt	145,835	151,605
Lease liabilities including current portion	(30,364)	(29,402)
Total Debt	115,471	122,203
Cash	(52,192)	(22,142)
Net Debt	63,279	100,061

Working capital is a measure of liquid assets that is calculated by taking current assets and subtracting current liabilities. Given that the Company is currently indebted, it uses it as an indicator of its financial efficiency and aims to maintain it at the lowest possible level.

Working capital ratio is calculated by dividing current assets by current liabilities.

Working capital is reconciled to the most comparable IFRS measure:

(in thousands of U.S. dollars)	As at September 30, 2025	As at December 31, 2024
	\$	\$
Inventories	153,792	137,823
Other current assets excluding inventories	135,759	79,572
Current assets	289,551	217,395
Current liabilities	(97,406)	(60,481)
Working capital	192,145	156,914
Working capital ratio	2.97	3.59

# **Additional Information**

5N+'s common shares trade on the Toronto Stock Exchange (TSX) under the ticker symbol VNP. Additional information relating to the Company, including the Company's annual information form, is available under the Company's profile on SEDAR+ at <a href="https://www.sedarplus.com">www.sedarplus.com</a>.

# **Selected Quarterly Financial Information**

(in thousands of U.S. dollars, except per	Sept 30,	June 30,	March 31,	Dec 31,	Sept 30,	June 30,	March 31,	Dec 31,
share amounts)	2025	2025	2025	2024	2024	2024	2024	2023
	\$	\$	\$	\$	\$	\$	\$	\$
Revenue	104,895	95,311	88,888	70,854	78,828	74,580	65,019	65,063
EBITDA	31,746	23,894	19,953	10,240	14,368	13,196	11,764	7,736
Adjusted EBITDA	29,055	24,146	20,792	12,484	15,621	13,490	11,737	9,033
Net earnings	18,176	15,227	9,573	1,006	6,370	4,789	2,507	2,284
Basic earnings per share	\$0.20	\$0.17	\$0.11	\$0.01	\$0.07	\$0.05	\$0.03	\$0.03
Diluted earnings per share	\$0.20	\$0.17	\$0.11	\$0.01	\$0.07	\$0.05	\$0.03	\$0.03
Adjusted net earnings	16,582	15,749	10,715	2,783	7,841	4,991	2,772	2,994
Basic adjusted earnings per share	\$0.19	\$0.18	\$0.12	\$0.03	\$0.09	\$0.06	\$0.03	\$0.03
Cash from operations before net change								
in non-cash working capital items	21,848	18,520	16,124	6,958	11,875	9,503	7,144	5,883
Backlog	311 days	297 days	268 days	326 days	289 days	300 days	288 days	292 days

Net earnings are completely attributable to equity holders of 5N+.